

News Releases

All Years

Search

Go

[Advanced Search](#)

MAY 9, 2022

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

MAR 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

FEB 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

FEB 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

Show 5  per page

[«](#) [1](#) [...](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [...](#) [16](#) [»](#)



